Abstract

; The mission of the Protocol Review and Monitoring System (PRMS) is to provide internal oversight of all cancer clinical trials conducted at the OHSU Knight Cancer Institute to ensure both scientific integrity and the protection of human subjects through the course of the clinical research process. The PRMS includes initial scientific protocol review, real-time monitoring of protocol activity, monthly cumulative report review, annual review and final review. All components of the PRMS at the Knight are the responsibility of the Clinical Research Review Committee (CRRC). The CRRC is charged by the Knight Cancer Institute Director to ensure that all clinical trials and cancer-related research conducted at the Institute are: 1) scientifically meritorious;2) appropriately designed and statistically validated;3) feasible for completion within the specified time frame;4) to ensure clinical trial compliance with FDA and NIH guidelines;and, 5) compatible with the priorities, goals, and interests of the Institute. The functions of the CRRC are independent of the OHSU Institutional Review Board (IRB) and the Data and Safety Monitoring Committee (DSMC).

Public Health Relevance

The mission of the Protocol Review and Monitoring System (PRMS) is to provide internal oversight of all cancer clinical trials conducted at the OHSU Knight Cancer Institute to ensure both scientific integrity and the protection of human subjects through the course of the clinical research process.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-16
Application #
8504966
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
16
Fiscal Year
2013
Total Cost
$54,868
Indirect Cost
$23,262

  Institution

Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239

  Publications

Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33

Showing the most recent 10 out of 277 publications